DAWN Rheumatology - February 2017 Newsletter
4S Information Systems Ltd

February 2017 DAWN Rheumatology Software E-Newsletter

In this issue:

Come and visit us at the BSR, Birmingham
4S DAWN will be exhibiting at this year’s British Society of Rheumatology meeting in Birmingham from April 25th - 27th.

Come and visit us at Stand R22 and take a look at the latest product developments within DAWN RH and speak to members of the 4S DAWN team who will be happy to discuss the product and offer demonstrations.

We look forward to seeing you there! 

DAWN Clinical Software User Workshop Success
Thank you to those customers who joined us for our recent DAWN Clinical Software Regional User Workshop at Hammersmith Hospital in London.  This informative workshop provided a great opportunity to share ideas, learn alternative methods of best practice and help customers get the most out of their DAWN software.

The workshop saw a wide spectrum of DAWN users in attendance, including nurses, consultants and administrators from Rheumatology, Dermatology, Gastroenterology and Neurology.

The morning session comprised of three customer presentations, a discussion forum and DAWN product developments, while the afternoon involved training sessions on a number of topics.

Look out for the Proceedings document from the workshop which will be available soon.

If you are interested in speaking at or attending future regional workshops then please contact Mel at

Effectively record patient risks in DAWN
Recording risks for patients in DAWN is simple with a visible record top-left on the patient screen.  See your DAWN Help manual for the easy steps to set up and use the Risks.  

Extra notes can be added to the patient record and higher risk can be highlighted.  Once a patient has a risk recorded, reports from your database can identify who is at risk.

For more information contact the 4S DAWN support team at

Resetting your DAWN password - help and guidance
Reset a forgotten password via email
In Version 7.9.44 of DAWN, the login screen was redesigned to include the option to reset a forgotten password by email.

If you forget your password, you can simply enter your email address and press the Reset button. So long as DAWN is configured to send emails and can identify you from your email address, it resets your password automatically and emails you a temporary password that you can use to log in.

When you log in using the temporary password, you are immediately prompted to change your temporary password for a new one of your choosing. The new Change Your Password form is much more helpful than before. It lists the rules which your new password has to meet. As you type, as soon as your password satisfies a rule (e.g. is at least 6 characters long) the red X symbol next to the rule turns to a green tick symbol. When all rules show a green tick, you know your new password is sufficiently strong.

To upgrade to the latest version of DAWN (Version 7.9.63) and take advantage of this and a range of other user and safety improvements, contact the 4S DAWN support team at

Reset your password via your System Administrator
If you do not have DAWN Version 7.9.44 or above, you should ask your DAWN System Administrator to reset your password.

This is usually a DAWN user who has full admin rights to the system.

Reset your password via DAWN support
Your should reset your password via the DAWN system or via your DAWN System Administrator in the first instance.

If you are unable to reset your password via either of these options you can email the 4S DAWN support team at and it can be reset for you.

New way to keep up to date and connect with 4S DAWN
You can now keep up to date with developments at 4S DAWN Clinical Software via our new Twitter account! 

Follow us @4SDAWN today for all the latest news and updates from 4S DAWN Clinical Software.

Don't forget you can also keep up to date with 4S DAWN Clinical Software via our LinkedIn page so connect with us today!

Expand your capabilities with DAWN
There are a number of add-on modules available for DAWN RH designed to help customers expand their capabilities and improve productivity and efficiency. The following modules are available for DAWN RH systems:

  • Questionnaires
  • Interfaces - test results, demographics, admission and discharge, GP summary, medications and many more

For more information about any of the additional modules, contact the 4S DAWN team today -

As the range of application areas covered by 4S DAWN Clinical Software increases, there has been lots of interest in using DAWN within other departments and many customers now have a number of DAWN systems installed within their hospital/Trust.

The DAWN software also covers the following areas:

  • Anticoagulation
  • Anaemia Management
  • Clinical Haematology
  • Dermatology
  • Gastroenterology
  • Heart Failure
  • Multiple Sclerosis
  • Respiratory
  • VTE Diagnosis and Assessment
If you or any of your colleagues would be interested in learning more about any of the areas above, contact the 4S DAWN team today at to discuss your requirements and see a demonstration of the software in action.

Did you know.....
Rheumatoid arthritis incidence is decreasing in the UK
During the years from 1990 to 2014, the prevalence of rheumatoid arthritis in the UK first rose a little up to 2005, and is now slowly falling, according to an analysis from the Clinical Practice Research Datalink (Rheumatology doi: 10.1093/rheumatology/kew468).

This was driven by a 1.6% decrease in the annual incidence of rheumatoid arthritis throughout that period. But the “middle east” of England remains disproportionately affected, with incidence remaining highest in East Midlands, Yorkshire, and Humber

If the reasons for this trend could be identified, it might generate new strategies for public health efforts to prevent RA.

Arthritis Drugs Get Nod From European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)
The CCHMP of the EMA has recommended approval of several drugs for rheumatoid arthritis (RA) and other conditions, such as Crohn's disease, at its January meeting.

The committee recommended approval of tofacitinib citrate (Xeljanz, Pfizer) in combination with methotrexate (MTX) for the treatment of adults with moderate to severe active RA who have not responded adequately to or who are intolerant of one or more disease-modifying antirheumatic drugs.

The committee also recommended approval of two adalimumab (Humira, AbbVie) biosimilar drugs: Amgevita and Solymbic, both from Amgen Europe BV.

Molecule Key to Joint Inflammation Identified, May Lead to Improved Arthritis Treatments
Researchers have identified a factor that controls immune cells’ entry into joints, which leads to arthritis in diseases such as systemic lupus erythematosus (SLE). Though they are studying other factors in the process, they believe these findings could lead to new treatments that are more effective in preventing arthritis.

“Inflammatory arthritis is caused when immune cells are recruited from the blood into the joint in a highly regulated process controlled by chemoattractants and adhesion receptors,” said Andrew Luster, MD, PhD, senior investigator of the study, “Complement C5a receptor is the key initiator of neutrophil adhesion igniting immune complex–induced arthritis.” It was published in the journal Science Immunology.

Copyright © 2017 4S Information Systems Ltd, All rights reserved.